We are live on ! Find out more
BGI

B Group Inc Portfolio holdings

AUM $213M
1-Year Est. Return 96.05%
This Fund
S&P 500
This Quarter Est. Return
+22.25%
1 Year Est. Return
+96.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$213M
AUM Growth
+$78.1M
Cap. Flow
+$17.1M
Cap. Flow %
8.04%
Top 10 Hldgs %
79.47%
Holding
22
New
2
Increased
5
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
FTH
Faeth Therapeutics
FTH
+$14.1M
2
NRXP icon
NRX Pharmaceuticals
NRXP
+$3.61M
3
AURA icon
Aura Biosciences
AURA
+$1.19M
4
GPCR icon
Structure Therapeutics
GPCR
+$553K
5
ADMA icon
ADMA Biologics
ADMA
+$501K

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$2.19M
2
APGE icon
Apogee Therapeutics
APGE
+$631K
3
SLNO
Soleno Therapeutics
SLNO
+$251K
4
REPL icon
Replimune Group
REPL
+$199K

Sector Composition

Rank Sector Weight
1 Healthcare 82.71%
2 Miscellaneous 17.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
1
PUT
Invesco QQQ Trust
QQQ
$487B
$36.8M 17.29%
+50,000
New +$34.4M
ADMA icon
2
ADMA Biologics
ADMA
$2.12B
$27.3M 12.82%
3,262,542
+55,000
+2% +$501K
PALI icon
3
Palisade Bio
PALI
$366M
$23.9M 11.2%
11,414,285
– –
NRXP icon
4
NRX Pharmaceuticals
NRXP
$149M
$16.7M 7.86%
4,091,767
+1,091,767
+36% +$3.61M
FTH
5
Faeth Therapeutics
FTH
$1.06B
$15.3M 7.16%
+610,169
New +$14.1M
TSHA icon
6
Taysha Gene Therapies
TSHA
$1.77B
$12.3M 5.76%
1,800,556
– –
PRAX icon
7
Praxis Precision Medicines
PRAX
$9.79B
$11.1M 5.22%
33,237
– –
CLLS
8
Cellectis
CLLS
$323M
$9.84M 4.62%
3,281,501
– –
ZLAB icon
9
Zai Lab
ZLAB
$2.9B
$8.56M 4.02%
450,646
– –
GPCR icon
10
Structure Therapeutics
GPCR
$3.34B
$7.51M 3.53%
140,000
+12,500
+10% +$553K
ORKA
11
Oruka Therapeutics
ORKA
$6.19B
$7.14M 3.35%
75,000
– –
IOVA icon
12
Iovance Biotherapeutics
IOVA
$3.99B
$6.24M 2.93%
1,500,000
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$7.72B
$6.21M 2.92%
70,000
-30,000
-30% -$2.19M
AURA icon
14
Aura Biosciences
AURA
$773M
$5.43M 2.55%
764,243
+166,667
+28% +$1.19M
ASMB icon
15
Assembly Biosciences
ASMB
$734M
$4.83M 2.27%
175,706
– –
DRUG
16
Bright Minds Biosciences
DRUG
$657M
$4.74M 2.22%
67,500
– –
RARE icon
17
Ultragenyx Pharmaceutical
RARE
$1.51B
$4.51M 2.12%
135,000
– –
SGHT icon
18
Sight Sciences
SGHT
$457M
$3.66M 1.72%
970,000
– –
FHTX icon
19
Foghorn Therapeutics
FHTX
$292M
$976K 0.46%
200,000
+98,000
+96% +$435K
APGE icon
20
Apogee Therapeutics
APGE
– –
-7,500
Closed -$631K
REPL icon
21
Replimune Group
REPL
$1.42B
– –
-26,000
Closed -$199K
SLNO
22
DELISTED
Soleno Therapeutics
SLNO
– –
-7,500
Closed -$251K

Similar funds

WPA
WIT Partners Advisory Singapore $213M AUM 9.8% 1-Year Est. Return
B
Birchbrook Bangor, Maine $213M AUM 17.67% 1-Year Est. Return
CCWP
Cedar Cove Wealth Partners Bloomington, Minnesota $213M AUM
4FG
4Thought Financial Group Syosset, New York $213M AUM 13.41% 1-Year Est. Return
KCM
KM Capital Management Austin, Texas $213M AUM 21.82% 1-Year Est. Return
LWP
LFG Wealth Partners Elizabethtown, Kentucky $213M AUM
EWM
Evergreen Wealth Management Williamston, Michigan $213M AUM 16.8% 1-Year Est. Return
HB
Horizon Bancorp Michigan City, Indiana $213M AUM 13.24% 1-Year Est. Return

B Group Inc's Q2 2026 Portfolio in Review

As of Q2 2026, B Group Inc held 22 positions worth $213M, up 58% from $135M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

B Group Inc deployed $17.1M of net new capital in Q2 2026, opening 2 new positions and adding to 5 existing holdings. Its largest new stake was Faeth Therapeutics: 610,169 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Spyre Therapeutics, an estimated $2.19M trimmed.

  • B Group Inc's largest Q2 2026 buy was Faeth Therapeutics: 610,169 shares worth $15.3M.
  • B Group Inc added most to NRX Pharmaceuticals in Q2 2026, an estimated $3.61M increase.
  • B Group Inc's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $2.19M.
  • B Group Inc fully exited Apogee Therapeutics in Q2 2026, selling an estimated $631K.
  • B Group Inc's ten largest holdings make up 79% of its $213M portfolio in Q2 2026.
  • B Group Inc opened 2 new positions and closed 3 in Q2 2026.
  • B Group Inc's portfolio value rose 58% quarter-over-quarter to $213M.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.